本研究旨在評估cabozantinib對比安慰劑對曾接受血管內皮生長因子受體（VEGFR）標靶治療後惡化的放射性碘難治性分化型甲狀腺癌（DTC）受試者的無惡化存活期（PFS）及客觀緩解率（ORR）的影響。
適應症：Differentiated Thyroid Cancer
收案條件
納入條件
- Histologically or cytologically confirmed diagnosis of Differentiated Thyroid Cancer (DTC)
- Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
- Previously treated with or deemed ineligible for treatment with Iodine- 131 for differentiated thyroid cancer (DTC)
- Previously treated with at least one of the following vascular endothelial growth factor receptor (VEGFR)-targeting tyrosine kinase inhibitor (TKI) agents for DTC: lenvatinib or sorafenib. Note: Up to two prior VEGFR-targeting TKI agents are allowed
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
排除條件
- Prior treatment with any of the following: Cabozantinib; Selective small-molecule v-raf murine sarcoma viral oncogene homolog B1 (BRAF) kinase inhibitor; More than 2 VEGFR-targeting TKI agents; More than 1 immune checkpoint inhibitor therapy; 1 systemic chemotherapy regimen (given as single agent or in combination with another chemotherapy agent)
- Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks or 5 half-lives of the agent, whichever is longer, before randomization
- Receipt of any type of anticancer antibody (including investigational antibody) or systemic chemotherapy within 4 weeks before randomization
- Receipt of radiation therapy for bone metastasis within 2 weeks or any other radiation therapy within 4 weeks before randomization.
- Known brain metastases or cranial epidural disease unless adequately treated
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。